China’s KRAS Race: Homegrown Contenders Play Catch-Up

Gaining On In-Licensed Assets

 
• By Dexter Jie Yan
  
balance
balance seems to have been tipped towards home-grown KRAS G12C inhibitors in China • Source: Shutterstock

More from China

More from Focus On Asia